Hypertrophic cardiomyopathy screening

Hypertrophic Cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypertrophic Cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypertrophic cardiomyopathy screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypertrophic cardiomyopathy screening
CDC on Hypertrophic cardiomyopathy screening
Hypertrophic cardiomyopathy screening in the news
Blogs on Hypertrophic cardiomyopathy screening
Directions to Hospitals Treating Hypertrophic cardiomyopathy
Risk calculators and risk factors for Hypertrophic cardiomyopathy screening

Overview

Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1], Martin S. Maron, M.D., and Barry J. Maron, M.D.

Screening for hypertrophic cardiomyopathy

• Screening for hypertrophic cardiomyopathy(HCM) is a controversial subject in the medical community, as HCM is the leading cause of sudden death in athletes.
• AHA/ACC recommends that family history of the athlete should be sorted for any incidence of sudden death or presence of HCM in any of the family members.
• If family history is positive, physical examination and echocardiography should be done.

• In Italy, all competitive athletes are required to go through pre-participation screening of HCM
• This particular program has been in existence since 1982, and screening generally includes:

  • 12-lead ECG
  • General and cardiovascular physical examination, including blood pressure measurements
  • Family history

• Over 3 million competitive athletes are evaluated each year, and athletes judged to be free of cardiovascular disease receive a certificate enabling them to participate in competitive athleticsitalyref1
• In a study done in Italy over a 9-year period (1990-1998), 4450 competitive athletes were screened for HCM. Based on echocardiographic evaluation, 4397 of the athletes were excluded from a clinical diagnosis of HCMitalyref1

  • 41 of the 4450 athletes showed LV hypertrophy, with increased wall thicknesses, with four athletes being on the border, with maximal LV wall thickness of 13 mm